{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:33:33Z","timestamp":1790087613945,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003789","name":"Helwan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003789","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite the beneficial therapeutic effects of tamoxifen (TAMX) against breast cancer, long-term treatment with TAMX enhances the development of metabolic dysfunction-associated steatotic liver disease (MASLD), including steatohepatitis. Bempedoic acid (BA) is a recently approved lipid-lowering drug for dyslipidemia. Our study aimed to examine the potential impact of BA against TAMX-induced steatohepatitis in rats and underline the possible molecular pathways involved. Twenty-four adult female rats were allocated into 4 groups (<jats:italic>n<\/jats:italic>\u2009=\u20096): Control, TAMX (45 mg\/kg), BA (15 mg\/kg), and BA (30 mg\/kg) groups. BA was given orally by gavage for 15 consecutive days. TAMX was administered to all rats except the normal control rats. Co<jats:bold>-<\/jats:bold>treatment of BA with TAMX showed well-organized structures of the hepatocytes in the histopathological sections. BA significantly improved liver function and lipid profile, demonstrating dose-dependent hepatoprotective effects. Mechanistically, BA significantly decreased oxidative stress by decreasing the level of malondialdehyde (MDA) and increasing the level of superoxide dismutase (SOD), significantly reduced inflammatory cytokines such as nuclear factor-kappa B (NF-\u03baB\/p65) and tumor necrosis factor-alpha (TNF-\u03b1), significantly inhibited lipogenesis by decreasing sterol regulatory element binding protein 1c (SREBP-1c), fatty acid synthetase (FAS), acetyl-coenzyme A carboxylases (ACC), ATP-citrate lyase (ACL), and significantly promoted fatty acid oxidation be enhancing carnitine palmitoyl transferase 1 significantly (CPT-1) through AMP-activated protein kinase (AMPK) activation. These findings suggest BA as a potential adjunct therapy for TAMX-induced metabolic dysfunction-associated steatohepatitis (MASH).\n<\/jats:p>","DOI":"10.1007\/s00210-025-04047-5","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T03:54:52Z","timestamp":1744257292000},"page":"12661-12672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Protective potential of bempedoic acid as an AMPK activator in tamoxifen-induced steatohepatitis in rats"],"prefix":"10.1007","volume":"398","author":[{"given":"Mona","family":"Mosaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed K.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy M.","family":"El Morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"4047_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/fcp.12720","volume":"36","author":"E Abd El-Haleim","year":"2022","unstructured":"Abd El-Haleim E, Sallam N (2022) Vitamin D modulates hepatic microRNAs and mitigates tamoxifen-induced steatohepatitis in female rats. Fundam Clin Pharmacol 36:338\u2013349. https:\/\/doi.org\/10.1111\/fcp.12720","journal-title":"Fundam Clin Pharmacol"},{"key":"4047_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121573","volume":"320","author":"A Ahmed","year":"2023","unstructured":"Ahmed A, Mohamed S, Nofal S, El Morsy E, Ahmed A (2023) Effect of bempedoic acid on angiotensin-II induced hypertension and vascular tissue remodelling in renal hypertensive rats through AMPK multiple signalling pathways modulation. Life Sci 320:121573. https:\/\/doi.org\/10.1016\/j.lfs.2023.121573","journal-title":"Life Sci"},{"key":"4047_CR3","doi-asserted-by":"publisher","unstructured":"Bekheit M, Kamera B, Colacino L, Dropmann A, Delibegovic M, Almadhoob F, Hanafy N, Bermano G, Hammad S (2025) Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease. EXCLI journal 24. https:\/\/doi.org\/10.17179\/excli2024-7718","DOI":"10.17179\/excli2024-7718"},{"key":"4047_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1028355","volume":"9","author":"G Biolo","year":"2022","unstructured":"Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, Mearelli F, Di Girolamo F (2022) Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front Cardiovasc Med 9:1028355. https:\/\/doi.org\/10.3389\/fcvm.2022.1028355","journal-title":"Front Cardiovasc Med"},{"key":"4047_CR5","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/j.clbc.2017.11.010","volume":"18","author":"H Chang","year":"2018","unstructured":"Chang H, Pan H, Lee C (2018) Prevention of tamoxifen-related nonalcoholic fatty liver disease in breast cancer patients. Clin Breast Cancer 18:e677\u2013e685. https:\/\/doi.org\/10.1016\/j.clbc.2017.11.010","journal-title":"Clin Breast Cancer"},{"key":"4047_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/hep.23813","volume":"52","author":"L Cole","year":"2010","unstructured":"Cole L, Jacobs R, Vance D (2010) Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 52:1258\u20131265. https:\/\/doi.org\/10.1002\/hep.23813","journal-title":"Hepatology"},{"key":"4047_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/14737140.2018.1520096","volume":"18","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Vaz-Luis I (2018) Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther 18:1101\u20131112. https:\/\/doi.org\/10.1080\/14737140.2018.1520096","journal-title":"Expert Rev Anticancer Ther"},{"key":"4047_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1381\/0960892053576596","volume":"15","author":"A Cuadrado","year":"2005","unstructured":"Cuadrado A, Orive A, Garc\u00eda C, Dom\u00ednguez A, Fern\u00e1ndez J, Crespo J, Pons F (2005) Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 15:442\u2013446. https:\/\/doi.org\/10.1381\/0960892053576596","journal-title":"Obes Surg"},{"key":"4047_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.269.14.1829","volume":"269","author":"C Dinarello","year":"1993","unstructured":"Dinarello C, Gelfand J, Wolff S (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829\u20131835. https:\/\/doi.org\/10.1001\/jama.269.14.1829","journal-title":"JAMA"},{"key":"4047_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174337","volume":"908","author":"R El-Asfar","year":"2021","unstructured":"El-Asfar R, El-Derany M, Sallam A, Wahdan S, El-Demerdash E, Sayed S, El-Mesallamy H (2021) Luteolin mitigates tamoxifen-associated fatty liver and cognitive impairment in rats by modulating beta-catenin. Eur J Pharmacol 908:174337. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174337","journal-title":"Eur J Pharmacol"},{"key":"4047_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/15376516.2019.1669243","volume":"30","author":"A Famurewa","year":"2020","unstructured":"Famurewa A, Ekeleme C, David E, Eleazu C, Folawiyo A, Obasi N (2020) Zinc abrogates anticancer drug tamoxifen-induced hepatotoxicity by suppressing redox imbalance, NO\/iNOS\/NF-\u0138B signaling, and caspase-3-dependent apoptosis in female rats. Toxicol Mech Methods 30:115\u2013123. https:\/\/doi.org\/10.1080\/15376516.2019.1669243","journal-title":"Toxicol Mech Methods"},{"key":"4047_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"W Friedewald","year":"1972","unstructured":"Friedewald W, Levy R, Fredrickson D (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502. https:\/\/doi.org\/10.1093\/clinchem\/18.6.499","journal-title":"Clin Chem"},{"key":"4047_CR13","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1194\/jlr.M600148-JLR200","volume":"47","author":"O Gudbrandsen","year":"2006","unstructured":"Gudbrandsen O, Rost T, Berge R (2006) Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 47:2223\u20132232. https:\/\/doi.org\/10.1194\/jlr.M600148-JLR200","journal-title":"J Lipid Res"},{"key":"4047_CR14","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00204-018-2254-4","volume":"92","author":"S Hammad","year":"2018","unstructured":"Hammad S, Othman A, Meyer C, Telfah A, Lambert J, Dewidar B, Werle J, Nwosu Z, Mahli A, Dormann C, Gao Y, Gould K, Han M, Yuan X, Gogiashvili M, Hergenr\u00f6der R, Hellerbrand C, Thomas M, Ebert M, Amasheh S, Hengstler J, Dooley S (2018) Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulation. Arch Toxicol 92:2549\u20132561. https:\/\/doi.org\/10.1007\/s00204-018-2254-4","journal-title":"Arch Toxicol"},{"key":"4047_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41419-023-05855-4","volume":"14","author":"S Hammad","year":"2023","unstructured":"Hammad S, Ogris C, Othman A, Erdoesi P, Schmidt H, Biermayer I, Helm B, Gao Y, Pioro\u0144ska W, Holland C, D\u2019alessandro L, De La Torre C, Sticht C, Al Aoua S, Theis F, Bantel H, Ebert M, Klingm\u00fcller U, Hengstler J, Dooley S, Mueller N (2023) Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation. Cell Death Dis 14:414. https:\/\/doi.org\/10.1038\/s41419-023-05855-4","journal-title":"Cell Death Dis"},{"key":"4047_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s13530-018-0376-y","volume":"10","author":"N Hassanein","year":"2018","unstructured":"Hassanein N, Ali A, El-Khawaga A (2018) Methylseleninic acid and grape seed extract alleviate tamoxifen induce hepatotoxicity in rats. Toxicol Environ Heal Sci 10:278\u2013287. https:\/\/doi.org\/10.1007\/s13530-018-0376-y","journal-title":"Toxicol Environ Heal Sci"},{"key":"4047_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/dna.2014.2630","volume":"34","author":"B Huang","year":"2015","unstructured":"Huang B, Lin C, Chen H, Lin J, Cheng Y, Kao S (2015) AMPK activation inhibits expression of proinflammatory mediators through downregulation of PI3K\/p38 MAPK and NF-\u03baB signaling in murine macrophages. DNA Cell Biol 34:133\u2013141. https:\/\/doi.org\/10.1089\/dna.2014.2630","journal-title":"DNA Cell Biol"},{"key":"4047_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2020.108656","volume":"160","author":"A Ismail","year":"2020","unstructured":"Ismail A, Doghish A, Elsadek B, Salama S, Mariee A (2020) Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase. Steroids 160:108656. https:\/\/doi.org\/10.1016\/j.steroids.2020.108656","journal-title":"Steroids"},{"key":"4047_CR19","doi-asserted-by":"publisher","first-page":"10219","DOI":"10.1007\/s11033-023-08847-x","volume":"50","author":"G Kamel","year":"2023","unstructured":"Kamel G, Elariny H (2023) Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1\/Nrf2\/HO-1 and SIRT1\/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis. Mol Biol Rep 50:10219\u201310233. https:\/\/doi.org\/10.1007\/s11033-023-08847-x","journal-title":"Mol Biol Rep"},{"key":"4047_CR20","doi-asserted-by":"publisher","unstructured":"Kim T, Kim Y, Cheong J, Cho S, Kim S (2018) Tamoxifen-Induced Non-alcoholic Steatohepatitis Cirrhosis. Soonchunhyang Medical Science 24:81\u201384. https:\/\/doi.org\/10.15746\/sms.18.014","DOI":"10.15746\/sms.18.014"},{"key":"4047_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"D Kleiner","year":"2005","unstructured":"Kleiner D, Brunt E, Natta V, Behling C, Contos M, Cummings O, Ferrell L, Liu Y, Torbenson M, Unalp A, Yeh M, Mccullough A, Sanyal A (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"4047_CR22","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.prp.2018.09.030","volume":"214","author":"S Leal","year":"2018","unstructured":"Leal S, Rocha L, Silva A, Faria J, Dinis O, S\u00e1 S (2018) Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy. Pathol Res Pract 214:2115\u20132120. https:\/\/doi.org\/10.1016\/j.prp.2018.09.030","journal-title":"Pathol Res Pract"},{"key":"4047_CR23","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/liv.14434","volume":"40","author":"B Lee","year":"2020","unstructured":"Lee B, Jung E, Yoo J, Kim S, Lee C, Kim Y, Jeong S, Jang J, Lee S, Kim H, Jun B, Kim Y, Cheon G (2020) Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease. Liver Int 40:1344\u20131355. https:\/\/doi.org\/10.1111\/liv.14434","journal-title":"Liver Int"},{"key":"4047_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/toxres\/tfac043","volume":"11","author":"M Li","year":"2022","unstructured":"Li M, Cai Y, Chen X, Zhang L, Jiang Z, Yu Q (2022) Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation. Toxicol Res (Camb) 11:673\u2013682. https:\/\/doi.org\/10.1093\/toxres\/tfac043","journal-title":"Toxicol Res (Camb)"},{"key":"4047_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40139-013-0022-y","volume":"1","author":"J Massart","year":"2013","unstructured":"Massart J, Begriche K, Buron N, Porceddu M, Borgne S, Fromenty B (2013) Drug-induced inhibition of mitochondrial fatty acid oxidation and steatosis. Current Pathobiology Reports 1:147\u2013157. https:\/\/doi.org\/10.1007\/s40139-013-0022-y","journal-title":"Current Pathobiology Reports"},{"key":"4047_CR26","doi-asserted-by":"crossref","unstructured":"Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro F, Gasbarrini A , Grieco A (2017) Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci 21:86\u201394. https:\/\/doi.org\/10.14218\/JCTH.2020.00091","DOI":"10.14218\/JCTH.2020.00091"},{"key":"4047_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"S Nissen","year":"2023","unstructured":"Nissen S, Lincoff A, Brennan D, Ray K, Mason D, Kastelein J, Thompson P, Libby P, Cho L, Plutzky J, Bays H, Moriarty P, Menon V, Grobbee D, Louie M, Chen C, Li N, Bloedon L, Robinson P, Horner M, Sasiela W, Mccluskey J, Davey D, Fajardo P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls S (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388:1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024","journal-title":"N Engl J Med"},{"key":"4047_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1590\/S0212-16112011000300003","volume":"26","author":"P Pettinelli","year":"2011","unstructured":"Pettinelli P, Obreg\u00f3n A, Videla L (2011) Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp 26:441\u2013450. https:\/\/doi.org\/10.1590\/S0212-16112011000300003","journal-title":"Nutr Hosp"},{"key":"4047_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","volume":"28","author":"S Reitman","year":"1957","unstructured":"Reitman S, Frankel S (1957) A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:56\u201363. https:\/\/doi.org\/10.1093\/ajcp\/28.1.56","journal-title":"Am J Clin Pathol"},{"key":"4047_CR30","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez R, Samino S, Girona J, Mart\u00ednez N, R\u00e0fols P, Garc\u00eda M, Guaita S, Junza A, Heras M, Yanes O, Correig X , Masana L (2020) Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms. Biomolecules 10. https:\/\/doi.org\/10.3390\/biom10091275","DOI":"10.3390\/biom10091275"},{"key":"4047_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00109-011-0748-0","volume":"89","author":"A Salminen","year":"2011","unstructured":"Salminen A, Hyttinen J, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-\u03baB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 89:667\u2013676. https:\/\/doi.org\/10.1007\/s00109-011-0748-0","journal-title":"J Mol Med (Berl)"},{"key":"4047_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100051","volume":"2","author":"K Sanjay","year":"2021","unstructured":"Sanjay K, Vishwakarma S, Zope B, Mane V, Mohire S, Dhakshinamoorthy S (2021) ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. Curr Res Pharmacol Drug Discov 2:100051. https:\/\/doi.org\/10.1016\/j.crphar.2021.100051","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"4047_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5604\/16652681.1171749","volume":"14","author":"S Satapathy","year":"2015","unstructured":"Satapathy S, Kuwajima V, Nadelson J, Atiq O, Sanyal A (2015) Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol 14:789\u2013806. https:\/\/doi.org\/10.5604\/16652681.1171749","journal-title":"Ann Hepatol"},{"key":"4047_CR34","doi-asserted-by":"publisher","first-page":"R779","DOI":"10.1152\/ajpregu.00243.2016","volume":"311","author":"D Sepa-Kishi","year":"2016","unstructured":"Sepa-Kishi D, Wu M, Uthayakumar A, Mohasses A, Ceddia R (2016) Antilipolytic and antilipogenic effects of the CPT-1b inhibitor oxfenicine in the white adipose tissue of rats. Am J Physiol Regul Integr Comp Physiol 311:R779-r787. https:\/\/doi.org\/10.1152\/ajpregu.00243.2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"4047_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jcmgh.2023.12.012","volume":"17","author":"S Wang","year":"2024","unstructured":"Wang S, Link F, Han M, Chaudhary R, Asimakopoulos A, Liebe R, Yao Y, Hammad S, Dropmann A, Krizanac M, Rubie C, Feiner L, Glanemann M, Ebert M, Weiskirchen R, Henis Y, Ehrlich M, Dooley S (2024) The interplay of TGF-\u03b21 and cholesterol orchestrating hepatocyte cell fate, EMT, and signals for HSC activation. Cell Mol Gastroenterol Hepatol 17:567\u2013587. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.12.012","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"4047_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.bbagen.2013.10.034","volume":"1840","author":"S Wu","year":"2014","unstructured":"Wu S, Wu Y, Wu T, Wei Y (2014) Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochim Biophys Acta 1840:1331\u20131344. https:\/\/doi.org\/10.1016\/j.bbagen.2013.10.034","journal-title":"Biochim Biophys Acta"},{"key":"4047_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236506","volume":"15","author":"J Yoo","year":"2020","unstructured":"Yoo J, Lim Y, Kim M, Lee B, Kim B, Kim Z, Lee J, Lee M, Kim S, Kim Y (2020) Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. PLoS ONE 15:e0236506. https:\/\/doi.org\/10.1371\/journal.pone.0236506","journal-title":"PLoS ONE"},{"key":"4047_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2019.124705","volume":"239","author":"Q Yu","year":"2020","unstructured":"Yu Q, Huo J, Zhang Y, Liu K, Cai Y, Xiang T, Jiang Z, Zhang L (2020) Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish. Chemosphere 239:124705. https:\/\/doi.org\/10.1016\/j.chemosphere.2019.124705","journal-title":"Chemosphere"},{"key":"4047_CR39","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.3390\/ijms15034019","volume":"15","author":"F Zhao","year":"2014","unstructured":"Zhao F, Xie P, Jiang J, Zhang L, An W, Zhan Y (2014) The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci 15:4019\u20134030. https:\/\/doi.org\/10.3390\/ijms15034019","journal-title":"Int J Mol Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04047-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:38:19Z","timestamp":1758256699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4047"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04047-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}